ClinicalTrials.gg
CompletedNCT04767529HarmonyUpdated Jun 18, 2025Results posted

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of Efruxifermin and Placebo in NASH - Nonalcoholic Steatohepatitis, sponsored by Akero Therapeutics, Inc. Completed at 55 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Akero Therapeutics, Inc (part of Novo Nordisk A/S) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S — 1 open to participants now, 4 under way, 3 of them phase 3. Non-alcoholic Fatty Liver Disease · Novo Nordisk A/S.

Enrollment
7th of 17
128 · median 71
Started
2021
with 4 others
Phase 2
6 of 18
none open now
Registered
7th of 18
by date

Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2021, is one of 6 in phase 2, and was the 7th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

1 of the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-pregnant, non-lactating females between 18 - 75 years of age inclusive, based on the date of the screening visit.
  • Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes.
  • FibroScan measurement > 8.5 kPa [kilopascal].
  • -proven NASH. Must have had a liver biopsy obtained ≤ 180 days prior to randomization with fibrosis stage 2 to 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:

    • Steatosis (scored 0 to 3),
    • Ballooning degeneration (scored 0 to 2), and
    • Lobular inflammation (scored 0 to 3).

Exclusion criteria

Exclusion Criteria:

  • Weight loss > 5% in the 3 months prior to screening until randomization or from the time of the diagnostic liver until randomization, whichever is longer.
  • Presence of cirrhosis on liver biopsy (stage 4 fibrosis).
  • Type 1 or uncontrolled Type 2 diabetes.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (actual)

Study arms

  • Placebo comparator
    placebo

    double-blind, once-weekly subcutaneous injection

    Drug: Placebo

  • Experimental
    Efruxifermin 28 mg

    double-blind, once-weekly subcutaneous injection

    Drug: Efruxifermin

  • Placebo comparator
    Efruxifermin 50 mg

    double-blind, once-weekly subcutaneous injection

    Drug: Efruxifermin

Interventions

  • subcutaneous injection

    Also known as: EFX

  • DrugPlacebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3)

    Proportions of subjects in EFX vs placebo groups with improvement in liver fibrosis, defined as ≥ 1 stage NASH Clinical Research Network \[CRN\] fibrosis score (score ranges from 0 to 4, increasing with fibrosis severity), and no worsening of steatohepatitis (no increase in NASH Activity Score \[NAS\], which ranges from 0 to 8 and is the sum of scores of steatosis, lobular inflammation, and hepatocyte ballooning), at Week 24

    Time frame: 24 Weeks

Secondary outcomes

  1. Proportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage and no Worsening of Steatohepatitis at Week 96

    Proportions of subjects in EFX vs baseline groups who achieve improvement in liver fibrosis (decrease of ≥ 1 stage in NASH CRN fibrosis score) and no worsening of steatohepatitis (no increase in NAS for ballooning, inflammation, or steatosis) at Week 96

    Time frame: 96 Weeks

  2. Proportion of Subjects Who Achieve Resolution of Steatohepatitis and no Worsening of Liver Fibrosis at Week 24 and Week 96

    Proportions of subjects in EFX vs placebo groups who achieve resolution of steatohepatitis (defined as a NAS of 0-1 for inflammation, 0 for ballooning, and any value for steatosis) and no worsening of liver fibrosis (determined by the NASH CRN criteria)

    Time frame: 24 and 96 weeks

  3. Proportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage at Week 24 and Week 96

    Proportion of subjects in EFX vs placebo groups who achieve improvement in liver fibrosis (decrease ≥ 1 stage in NASH CRN fibrosis score)

    Time frame: 24 and 96 Weeks

  4. Change From Baseline in Hepatic Fat Fraction in EFX vs Placebo Groups

    Change from baseline in hepatic fat fraction, measured by magnetic resonance imaging proton-density fat fraction (MRI-PDFF): Week 24 and Week 96 MRI-PDFF Analysis Set

    Time frame: 24 and 96 Weeks

  5. Change From Baseline in Lipoproteins at Week 24 and Week 96

    Change from baseline of lipoproteins (triglycerides, Non-HDL-C, HDL-C and LDL-C) in EFX vs placebo groups

    Time frame: 24 and 96 weeks

  6. Change From Baseline of Hemoglobin A1c (Glycated Hemoglobin, HbA1c) at Week 24 and Week 96

    Change from baseline in hemoglobin A1c (glycated hemoglobin, HbA1c) in EFX vs placebo groups

    Time frame: 24 Weeks, 96 Weeks

  7. Change From Baseline in C-peptide at Week 24 and Week 96

    Change from baseline in C-peptide in EFX vs placebo groups

    Time frame: 24 Weeks, 96 Weeks

  8. Change From Baseline in Adiponectin at Week 24 and Week 96

    Change from baseline in adiponectin in EFX vs placebo groups

    Time frame: 24 Weeks, 96 Weeks

  9. Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 24 and Week 96

    Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) in EFX vs placebo groups The Homeostatic Model Assessment of Insulin Resistance, HOMA-IR, is a calculated index that estimates insulin resistance based on fasting glucose and insulin levels. Higher values indicate greater insulin resistance. \< 1.0: Normal insulin sensitivity 1.0-1.9: Mild insulin resistance 2.0-2.9: Moderate insulin resistance \> 2.9: Severe insulin resistance

    Time frame: 24 Weeks, 96 Weeks

  10. Change From Baseline in Enhanced Liver Fibrosis (ELF) Score at Week 24 and Week 96

    Change from Baseline in Enhanced Liver Fibrosis (ELF) Score in EFX vs placebo groups The Enhanced Liver Fibrosis (ELF) score is a non-invasive blood test that assesses the risk of liver fibrosis and its progression. Lower risk (\<9.8): Suggests a lower risk of advanced liver fibrosis. Mid risk (9.8-11.2): Indicates a moderate risk of disease progression. Higher risk (≥11.3): Suggests a higher risk of developing cirrhosis or liver-related events

    Time frame: 24 and 96 Weeks

  11. Change From Baseline in N-terminal Type III Collagen Propeptide (Pro-C3) at Week 24 and Week 96

    Change from Baseline in N-terminal Type III Collagen Propeptide (Pro-C3) in EFX vs placebo groups

    Time frame: 24 and 96 Weeks

  12. Change From Baseline in Collagen III Neo-Peptide (C3M) at Week 24 and Week 96

    Change from Baseline in Collagen III Neo-Peptide (C3M) in EFX vs placebo groups

    Time frame: 24 and 96 Weeks

  13. Change From Baseline in NIS4 Score at Week 24 and Week 96

    Change from Baseline in NIS4 score in EFX vs placebo groups NIS4 scores range from 0 to 1 and are calculated by combining the results of four individual biomarker assays \[miR34a-5p, α2-macroglobulin (A2M), YKL-40 and HbA1c\] each of which contributes to the test's ability to detect liver inflammation and/or fibrosis. \>0.63: Higher risk of NASH or advanced fibrosis 0.37-0.63: Moderate risk, and additional testing may be considered \<0.36: Lower risk of of NASH or advanced fibrosis

    Time frame: 24 and 96 Weeks

  14. Change in Body Weight at Week 24 and Week 96

    Change from baseline in body weight (kg) in EFX vs placebo groups

    Time frame: 24 and 96 weeks

  15. Change From Baseline in Liver Stiffness (kPa) at Week 24 and Week 96

    Change from Baseline in Liver Stiffness Evaluated by FibroScan in EFX vs placebo groups at Week 24 and Week 96: Full Analysis Set

    Time frame: 24 and 96 weeks

07

Results

Posted May 8, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Started434243
Started study drug434043
Completed week 96 treatment342627
Discontinued treatment91616
Completed week 24 visit423736
Completed342727
Not completed91516
Withdrew: Adverse event043
Withdrew: Clinical outcomes endpoint (excluding death)133
Withdrew: Required use of a prohibited medication010
Withdrew: Withdrawal by subject754
Withdrew: At the discretion of the investigator or sponsor for noncompliance103
Withdrew: Lost to follow-up023

Outcome measures

PrimaryEffect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3)

Proportions of subjects in EFX vs placebo groups with improvement in liver fibrosis, defined as ≥ 1 stage NASH Clinical Research Network \[CRN\] fibrosis score (score ranges from 0 to 4, increasing with fibrosis severity), and no worsening of steatohepatitis (no increase in NASH Activity Score \[NAS\], which ranges from 0 to 8 and is the sum of scores of steatosis, lobular inflammation, and hepatocyte ballooning), at Week 24

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3)
ParticipantsPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3)81514
Statistical analysis
  • Placebo vs Efruxifermin 28 mg · Cochran-Mantel-Haenszel · p = 0.025 (Threshold for significance set at p\<0.05) · Percent difference: 22.6 · 95% CI 3.8 to 41.4% difference from placebo (efruxifermin 28 mg - placebo)
  • Placebo vs Efruxifermin 50 mg · Cochran-Mantel-Haenszel · p = 0.036 (Threshold for significance was p\<0.05) · Percent difference: 22.5 · 95% CI 1.6 to 43.3% difference from placebo (efruxifermin 50 mg - placebo)
SecondaryProportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage and no Worsening of Steatohepatitis at Week 96

Proportions of subjects in EFX vs baseline groups who achieve improvement in liver fibrosis (decrease of ≥ 1 stage in NASH CRN fibrosis score) and no worsening of steatohepatitis (no increase in NAS for ballooning, inflammation, or steatosis) at Week 96

Time frame:
96 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage and no Worsening of Steatohepatitis at Week 96
ParticipantsPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Proportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage and no Worsening of Steatohepatitis at Week 9681221
Statistical analysis
  • Placebo vs Efruxifermin 28 mg · Cochran-Mantel-Haenszel · p = 0.070 (Threshold for significance set at p\<0.05) · Percent difference: 21.8 · 95% CI -1.3 to 45.0A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between the efruxifermin 28 mg and placebo group
  • Placebo vs Efruxifermin 50 mg · Cochran-Mantel-Haenszel · p = <0.001 (Threshold for significance set at p\<0.05) · Percent difference: 51.9 · 95% CI 31.2 to 72.7A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between the efruxifermin 50 mg and placebo group
SecondaryProportion of Subjects Who Achieve Resolution of Steatohepatitis and no Worsening of Liver Fibrosis at Week 24 and Week 96

Proportions of subjects in EFX vs placebo groups who achieve resolution of steatohepatitis (defined as a NAS of 0-1 for inflammation, 0 for ballooning, and any value for steatosis) and no worsening of liver fibrosis (determined by the NASH CRN criteria)

Time frame:
24 and 96 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieve Resolution of Steatohepatitis and no Worsening of Liver Fibrosis at Week 24 and Week 96
ParticipantsPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Week 2461826
Week 9681616
Statistical analysis
  • Placebo vs Efruxifermin 28 mg · Cochran-Mantel-Haenszel · p = 0.002 (Threshold for significance set at p\<0.05) · Percent difference: 31.9 · 95% CI 12.9 to 50.9A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparison between the efruxifermin 28 mg and placebo group
  • Placebo vs Efruxifermin 50 mg · Cochran-Mantel-Haenszel · p = <0.001 (Threshold for significance set at p\<0.05) · Percent difference: 61.7 · 95% CI 44.1 to 79.4A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between the efruxifermin 50 mg and placebo groups
  • Placebo vs Efruxifermin 28 mg · Cochran-Mantel-Haenszel · p = 0.002 (Threshold for significance set at p\<0.05) · Percent difference: 38.9 · 95% CI 17.2 to 60.7A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between efruxifermin 28 mg and placebo groups
  • Placebo vs Efruxifermin 50 mg · Cochran-Mantel-Haenszel · p = 0.006 (Threshold for significance set at p\<0.05) · Percent difference: 33.2 · 95% CI 10.5 to 55.8A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between the efruxifermin 50 mg and placebo group
SecondaryProportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage at Week 24 and Week 96

Proportion of subjects in EFX vs placebo groups who achieve improvement in liver fibrosis (decrease ≥ 1 stage in NASH CRN fibrosis score)

Time frame:
24 and 96 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage at Week 24 and Week 96
ParticipantsPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Week 2491514
Week 9691221
Statistical analysis
  • Placebo vs Efruxifermin 28 mg · Cochran-Mantel-Haenszel · p = 0.053 (Threshold for significance set at p\<0.05) · Percent difference: 20.0 · 95% CI 0.4 to 39.5A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between the efruxifermin 28 mg and placebo group
  • Placebo vs Efruxifermin 50 mg · Cochran-Mantel-Haenszel · p = 0.069 (Threshold for statistical significance set at p\<0.05) · Percent difference: 19.9 · 95% CI -1.5 to 41.2A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between the efruxifermin 50 mg and placebo groups
  • Placebo vs Efruxifermin 28 mg · Cochran-Mantel-Haenszel · p = 0.123 (Threshold for significance set at p\<0.05) · Percent difference: 19 · 95% CI -4.8 to 42.8A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between the efruxifermin 28 mg and placebo groups
  • Placebo vs Efruxifermin 50 mg · Cochran-Mantel-Haenszel · p = <0.001 (Threshold for significance set at p\<0.05) · Percent difference: 49.0 · 95% CI 27.7 to 70.2A Cochran-Mantel-Haenszel test adjusting for stratification factors was used for comparisons between the efruxifermin 50 mg and placebo groups
SecondaryChange From Baseline in Hepatic Fat Fraction in EFX vs Placebo Groups

Change from baseline in hepatic fat fraction, measured by magnetic resonance imaging proton-density fat fraction (MRI-PDFF): Week 24 and Week 96 MRI-PDFF Analysis Set

Time frame:
24 and 96 Weeks
Reported as:
Mean · percentage hepatic fat
Change From Baseline in Hepatic Fat Fraction in EFX vs Placebo Groups
percentage hepatic fatPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Week 24-1.9 ± 0.78-8.8 ± 0.84-11.2 ± 0.86
Week 96-2.5 ± 0.89-6.3 ± 1.01-8.3 ± 1.00
Statistical analysis
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = <0.001 (Threshold for significance set at p\<0.05) · Mean difference (net): -6.9 · 95% CI -9.09 to -4.71MMRM: fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction and baseline as covariate for comparison
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = <0.001 (Threshold for significance set at p\<0.05) · Mean difference (net): -9.2 · 95% CI -11.47 to -7.02MMRM:fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction and baseline as covariates for comparison
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.005 (Threshold for significance set at p\<0.05) · Mean difference (net): -3.8 · 95% CI -6.39 to -1.18MMRM:fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction and baseline as covariates for comparison
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = <0.001 (Threshold for significance set at p\<0.05) · Mean difference (net): -5.8 · 95% CI -8.38 to -3.25MMRM:fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction and baseline as covariates for comparison
SecondaryChange From Baseline in Lipoproteins at Week 24 and Week 96

Change from baseline of lipoproteins (triglycerides, Non-HDL-C, HDL-C and LDL-C) in EFX vs placebo groups

Time frame:
24 and 96 weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline in Lipoproteins at Week 24 and Week 96
mg/dLPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in triglycerides (mg/dL) at Week 2410.5 ± 6.82-41.1 ± 7.26-44.7 ± 7.20
Change from baseline in triglycerides (mg/dL) at Week 9616.1 ± 7.69-26.9 ± 8.63-31.7 ± 8.54
Change from baseline in HDL cholesterol (mg/dL) at Week 24-0.9 ± 1.0910.1 ± 1.1611.5 ± 1.15
Change from baseline in HDL cholesterol (mg/dL) at Week 961.3 ± 1.437.3 ± 1.5910.7 ± 1.57
Change from baseline in LDL cholesterol (mg/dL) at Week 244.0 ± 3.47-10.4 ± 3.7-9.6 ± 3.69
Change from baseline in LDL cholesterol (mg/dL) at Week 96-1.3 ± 4.74-1.2 ± 5.29-1.4 ± 5.23
Change from baseline in non-HDL cholesterol (mg/dL) at Week 246.1 ± 3.83-16.6 ± 4.08-16.6 ± 4.05
Change from baseline in non-HDL cholesterol (mg/dL) at Week 961.5 ± 5.31-4.5 ± 5.92-6.7 ± 5.86
Statistical analysis
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = <0.001 · Mean difference (net): -51.6 · 95% CI -71.17 to -32.11
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = <0.001 · Mean difference (net): -55.2 · 95% CI -74.63 to -35.71
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = <0.001 (Threshold for significance set at p\<0.05) · Mean difference (net): -43.0 · 95% CI -65.73 to -20.27LS Means and differences, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX and placebo group
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = <0.001 (Threshold for significance set at p\<0.05) · Mean difference (net): -47.8 · 95% CI -70.39 to -25.24LS Means and differences, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX and placebo group
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = <0.001 · Mean difference (net): 11.0 · 95% CI 7.92 to 14.17
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = <0.001 · Mean difference (net): 12.5 · 95% CI 9.35 to 15.57
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.005 (Threshold for significance set at p\<0.05) · Mean difference (net): 6.0 · 95% CI 1.84 to 10.23LS Means and differences, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX and placebo group
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = <0.001 (Threshold for significance set at p\<0.05) · Mean difference (net): 9.5 · 95% CI 5.30 to 13.65LS Means and differences, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX and placebo group
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.005 · Mean difference (net): -14.4 · 95% CI -24.28 to -4.53
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = 0.007 · Median difference (net): -13.6 · 95% CI -23.50 to -3.76
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.990 (Threshold for significance set at p\<0.05) · Mean difference (net): 0.1 · 95% CI -13.86 to 14.04LS Means and differences, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX and placebo group
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = 0.980 (Threshold for significance set at p\<0.05) · Mean difference (net): -0.2 · 95% CI -14.07 to 13.71LS Means and differences, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX and placebo group
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = <0.001 · Mean difference (net): -22.6 · 95% CI -33.58 to -11.71
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = <0.001 · Mean difference (net): -22.7 · 95% CI -33.56 to -11.74
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.443 (Threshold for significance set at p\<0.05) · Mean difference (net): -6.1 · 95% CI -21.72 to 9.56LS Means and differences, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX and placebo group
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = 0.299 (Threshold for significance set at p\<0.05) · Mean difference (net): -8.2 · 95% CI -23.77 to 7.36LS Means and differences, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX and placebo group
SecondaryChange From Baseline of Hemoglobin A1c (Glycated Hemoglobin, HbA1c) at Week 24 and Week 96

Change from baseline in hemoglobin A1c (glycated hemoglobin, HbA1c) in EFX vs placebo groups

Time frame:
24 Weeks, 96 Weeks
Reported as:
Least squares mean · % glycated hemoglobin
Change From Baseline of Hemoglobin A1c (Glycated Hemoglobin, HbA1c) at Week 24 and Week 96
% glycated hemoglobinPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in hemoglobin A1C (HbA1c, %) at Week 24-0.0 ± 0.12-0.3 ± 0.12-0.4 ± 0.12
Change from baseline in hemoglobin A1C (HbA1c, %) at Week 96-0.0 ± 0.220.0 ± 0.240.2 ± 0.24
SecondaryChange From Baseline in C-peptide at Week 24 and Week 96

Change from baseline in C-peptide in EFX vs placebo groups

Time frame:
24 Weeks, 96 Weeks
Reported as:
Least squares mean · ng/mL
Change From Baseline in C-peptide at Week 24 and Week 96
ng/mLPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in C-Peptide at Week 240.0 ± 0.19-0.8 ± 0.20-1.2 ± 0.19
Change from baseline in C-Peptide at Week 96-0.2 ± 0.22-0.4 ± 0.25-1.0 ± 0.25
SecondaryChange From Baseline in Adiponectin at Week 24 and Week 96

Change from baseline in adiponectin in EFX vs placebo groups

Time frame:
24 Weeks, 96 Weeks
Reported as:
Least squares mean · ng/mL
Change From Baseline in Adiponectin at Week 24 and Week 96
ng/mLPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in adiponectin at Week 24296.4 ± 312.561411.5 ± 333.483088.8 ± 333.82
Change from baseline in adiponectin at Week 96531.5 ± 416.93975.3 ± 459.402018.3 ± 458.91
SecondaryChange From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 24 and Week 96

Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) in EFX vs placebo groups The Homeostatic Model Assessment of Insulin Resistance, HOMA-IR, is a calculated index that estimates insulin resistance based on fasting glucose and insulin levels. Higher values indicate greater insulin resistance. \< 1.0: Normal insulin sensitivity 1.0-1.9: Mild insulin resistance 2.0-2.9: Moderate insulin resistance \> 2.9: Severe insulin resistance

Time frame:
24 Weeks, 96 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 24 and Week 96
units on a scalePlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 240.7 ± 1.09-4.7 ± 1.19-5.6 ± 1.14
Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 96-1.3 ± 0.87-4.1 ± 1.01-5.5 ± 0.99
SecondaryChange From Baseline in Enhanced Liver Fibrosis (ELF) Score at Week 24 and Week 96

Change from Baseline in Enhanced Liver Fibrosis (ELF) Score in EFX vs placebo groups The Enhanced Liver Fibrosis (ELF) score is a non-invasive blood test that assesses the risk of liver fibrosis and its progression. Lower risk (\<9.8): Suggests a lower risk of advanced liver fibrosis. Mid risk (9.8-11.2): Indicates a moderate risk of disease progression. Higher risk (≥11.3): Suggests a higher risk of developing cirrhosis or liver-related events

Time frame:
24 and 96 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Enhanced Liver Fibrosis (ELF) Score at Week 24 and Week 96
score on a scalePlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in ELF Score at Week 240.1 ± 0.10-0.6 ± 0.10-0.7 ± 0.10
Change from baseline in ELF Score at Week 96-0.1 ± 0.14-0.7 ± 0.16-0.8 ± 0.16
SecondaryChange From Baseline in N-terminal Type III Collagen Propeptide (Pro-C3) at Week 24 and Week 96

Change from Baseline in N-terminal Type III Collagen Propeptide (Pro-C3) in EFX vs placebo groups

Time frame:
24 and 96 Weeks
Reported as:
Least squares mean · ng/mL
Change From Baseline in N-terminal Type III Collagen Propeptide (Pro-C3) at Week 24 and Week 96
ng/mLPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in N-terminal Type III Collagen Propeptide (Pro-C3) GEN2 at Week 24-2.7 ± 6.99-51.1 ± 7.37-53.9 ± 7.37
Change from baseline in N-terminal Type III Collagen Propeptide (Pro-C3) GEN2 at Week 96-17.2 ± 7.87-40.2 ± 8.89-50.5 ± 8.92
SecondaryChange From Baseline in Collagen III Neo-Peptide (C3M) at Week 24 and Week 96

Change from Baseline in Collagen III Neo-Peptide (C3M) in EFX vs placebo groups

Time frame:
24 and 96 Weeks
Reported as:
Least squares mean · ng/mL
Change From Baseline in Collagen III Neo-Peptide (C3M) at Week 24 and Week 96
ng/mLPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in Collagen III Neo-Peptide (C3M) (ng/mL) at Week 240.2 ± 0.35-0.8 ± 0.37-1.1 ± 0.38
Change from baseline in Collagen III Neo-Peptide (C3M) (ng/mL) at Week 963.1 ± 0.713.3 ± 0.804.4 ± 0.80
SecondaryChange From Baseline in NIS4 Score at Week 24 and Week 96

Change from Baseline in NIS4 score in EFX vs placebo groups NIS4 scores range from 0 to 1 and are calculated by combining the results of four individual biomarker assays \[miR34a-5p, α2-macroglobulin (A2M), YKL-40 and HbA1c\] each of which contributes to the test's ability to detect liver inflammation and/or fibrosis. \>0.63: Higher risk of NASH or advanced fibrosis 0.37-0.63: Moderate risk, and additional testing may be considered \<0.36: Lower risk of of NASH or advanced fibrosis

Time frame:
24 and 96 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in NIS4 Score at Week 24 and Week 96
score on a scalePlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in NIS-4 score at Week 24-0.0 ± 0.03-0.3 ± 0.04-0.3 ± 0.04
Change from baseline in NIS-4 score at Week 96-0.1 ± 0.05-0.2 ± 0.05-0.3 ± 0.05
SecondaryChange in Body Weight at Week 24 and Week 96

Change from baseline in body weight (kg) in EFX vs placebo groups

Time frame:
24 and 96 weeks
Reported as:
Least squares mean · kg
Change in Body Weight at Week 24 and Week 96
kgPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from Baseline in Body Weight (kg) at Week 24-0.6 ± 0.82-0.2 ± 0.86-3.0 ± 0.85
Change from Baseline in Body Weight (kg) at Week 96-1.5 ± 1.40-0.3 ± 1.53-3.5 ± 1.52
Statistical analysis
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.750 (Threshold for significance set at p\<0.05) · Mean difference (net): 0.4 · 95% CI -1.96 to 2.72
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = 0.042 (Threshold for significance set at p\<0.05) · Mean difference (net): -2.4 · 95% CI -4.75 to -0.09
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.564 · Mean difference (net): 1.2 · 95% CI -2.90 to 5.29
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = 0.348 · Mean difference (net): -1.9 · 95% CI -6.02 to 2.14
SecondaryChange From Baseline in Liver Stiffness (kPa) at Week 24 and Week 96

Change from Baseline in Liver Stiffness Evaluated by FibroScan in EFX vs placebo groups at Week 24 and Week 96: Full Analysis Set

Time frame:
24 and 96 weeks
Reported as:
Least squares mean · kPa
Change From Baseline in Liver Stiffness (kPa) at Week 24 and Week 96
kPaPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
Change from baseline in liver stiffness measurement (LSM, kPa) at Week 24-0.8 ± 0.88-2.9 ± 0.93-4.2 ± 0.95
Change from baseline in liver stiffness measurement (LSM, kPa) at Week 96-0.6 ± 0.98-4.0 ± 1.09-7.2 ± 1.08
Statistical analysis
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.102 · Mean difference (net): -2.1 · 95% CI -4.5 to 0.4
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = 0.009 · Mean difference (net): -3.3 · 95% CI -5.8 to -0.8
  • Placebo vs Efruxifermin 28 mg · Mixed Models Analysis · p = 0.021 (Threshold for significance set at P\<0.05) · Mean difference (net): -3.4 · 95% CI -6.2 to -0.5LS Means, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX 28 mg and placebo group
  • Placebo vs Efruxifermin 50 mg · Mixed Models Analysis · p = <0.001 · Mean difference (net): -6.6 · 95% CI -9.4 to -3.7LS Means, SEs, and p-values are from a MMRM with fixed effects of treatment, stratification factors, post-baseline visit, treatment-by-visit interaction, and baseline as a covariate for comparisons between the EFX 50 mg and placebo group

Adverse events

Collected over 96 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/43 (0%)4/43 (9.3%)42/43 (97.7%)
Efruxifermin 28 mg0/40 (0%)4/40 (10%)38/40 (95%)
Efruxifermin 50 mg0/43 (0%)7/43 (16.3%)43/43 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
GastritisGastrointestinal disorders0/431/400/43
PancreatitisGastrointestinal disorders0/431/400/43
Arteriospasm coronaryCardiac disorders0/431/400/43
ankle fractureInjury, poisoning and procedural complications0/431/400/43
Lower limb fractureInjury, poisoning and procedural complications0/431/400/43
Panic attackPsychiatric disorders0/431/400/43
Esophagitis ulcerativeGastrointestinal disorders0/430/401/43
Pancreatitis, necrotizingGastrointestinal disorders0/430/401/43
Non-cardiac chest painGeneral disorders1/430/401/43
chest painGeneral disorders0/430/401/43
Most frequent other events
Showing 10 of 55
Most frequent other events
EventPlaceboEfruxifermin 28 mgEfruxifermin 50 mg
DiarrheaGastrointestinal disorders13/4323/4019/43
NauseaGastrointestinal disorders13/4316/4019/43
COVID-19Infections and infestations13/4310/4016/43
injection-site erythemaGeneral disorders8/4310/408/43
Increased appetiteMetabolism and nutrition disorders3/438/4010/43
Frequent bowel movementsGastrointestinal disorders1/439/400/43
VomitingGastrointestinal disorders7/438/408/43
Injection-site bruisingGeneral disorders7/438/406/43
Procedural painInjury, poisoning and procedural complications7/438/405/43
HypertensionVascular disorders1/438/405/43

Baseline characteristics

Randomly assigned to groups

Age, Categorical
Age, Categorical(Participants)PlaceboEfruxifermin 28 mgEfruxifermin 50 mgTotal
<=18 years0000
Between 18 and 65 years343137102
>=65 years911626
Age, Continuous
Age, Continuous(years)PlaceboEfruxifermin 28 mgEfruxifermin 50 mgTotal
Mean55.0 ± 10.156.5 ± 9.352.4 ± 11.454.7 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEfruxifermin 28 mgEfruxifermin 50 mgTotal
Female27292379
Male16132049
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEfruxifermin 28 mgEfruxifermin 50 mgTotal
Hispanic or Latino15172052
Not Hispanic or Latino28252376
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEfruxifermin 28 mgEfruxifermin 50 mgTotal
Race — White393841118
Race — Black or African American2114
Race — Asian2305
Race — Native Hawaiian or Other Pacific Islander0000
Race — American Indian or Alaskan Native0000
Race — Other0011
Region of Enrollment
Region of Enrollment(participants)PlaceboEfruxifermin 28 mgEfruxifermin 50 mgTotal
United States434243128
Baseline Fibrosis Stage
Baseline Fibrosis Stage(Participants)PlaceboEfruxifermin 28 mgEfruxifermin 50 mgTotal
Fibrosis stage 213151644
Fibrosis stage 330272784
Weight
Weight(kg)PlaceboEfruxifermin 28 mgEfruxifermin 50 mgTotal
Mean107.6 ± 25.6103.9 ± 22.7102.8 ± 21.1104.8 ± 23.2

1 further baseline measures are reported on the registry.

08

Study locations

55 sites
  • Akero Clinical Study Site
    Chandler, Arizona 85224, United States
  • Akero Clinical Study Site
    Glendale, Arizona 85304, United States
  • Akero Clinical Study Site
    Tucson, Arizona 85712, United States
  • Akero Clinical Study Site
    North Little Rock, Arkansas 72117, United States
  • Akero Clinical Study Site
    Chula Vista, California 91910, United States
  • Akero Clinical Study Site
    Fresno, California 93720, United States
  • Akero Clinical Study Site
    La Jolla, California 92037, United States
  • Akero Clinical Study Site
    Los Angeles, California 90036, United States
  • Akero Clinical Study Site
    Los Angeles, California 90048, United States
  • Akero Clinical Study Site
    Los Angeles, California 90057, United States
  • Akero Clinical Study Site
    Orange, California 92866, United States
  • Akero Clinical Study Site
    Panorama City, California 91402, United States
  • Akero Clinical Study Site
    Rialto, California 92866, United States
  • Akero Clinical Study Site
    Santa Ana, California 92704, United States
  • Akero Clinical Study Site
    Fort Myers, Florida 33912, United States
  • Akero Clinical Study Site
    Inverness, Florida 34452, United States
  • Akero Clinical Study Site
    Lakewood Ranch, Florida 34211, United States
  • Akero Clinical Study Site
    Miami Lakes, Florida 33016, United States
  • Akero Clinical Study Site
    Miami, Florida 33134, United States
  • Akero Clinical Study Site
    Miami, Florida 33147, United States
  • Akero Clinical Study Site
    Ocala, Florida 34471, United States
  • Akero Clinical Study Site
    Sarasota, Florida 94240, United States
  • Akero Clinical Study Site
    Marietta, Georgia 30060, United States
  • Akero Clinical Study Site
    Topeka, Kansas 66606, United States
  • Akero Clinical Study Site
    Baton Rouge, Louisiana 70809, United States
  • Akero Clinical Study Site
    Marrero, Louisiana 70072, United States
  • Akero Clinical Study Site
    Ypsilanti, Michigan 48197, United States
  • Akero Clinical Study Site
    Flowood, Mississippi 39232, United States
  • Akero Clinical Study Site
    Jackson, Mississippi 39216, United States
  • Akero Clinical Study Site
    Las Vegas, Nevada 89106, United States
  • Akero Clinical Study Site
    Charlotte, North Carolina 28204, United States
  • Akero Clinical Study Site
    Durham, North Carolina 27712, United States
  • Akero Clinical Study Site
    Morehead City, North Carolina 28557, United States
  • Akero Clinical Study Site
    Cincinnati, Ohio 45219, United States
  • Akero Clinical Study Site
    Greenville, South Carolina 29605, United States
  • Akero Clinical Study Site
    Hermitage, Tennessee 37076, United States
  • Akero Clinical Study Site
    Nashville, Tennessee 37211, United States
  • Akero Clinical Study Site
    Arlington, Texas 76012, United States
  • Akero Clinical Study Site
    Austin, Texas 78757, United States
  • Akero Clinical Study Site
    Cedar Park, Texas 75246, United States
  • Akero Clinical Study Site
    Dallas, Texas 75234, United States
  • Akero Clinical Study Site
    Dallas, Texas 75246, United States
  • Akero Clinical Study Site
    Edinburg, Texas 78539, United States
  • Akero Clinical Study Site
    Fort Worth, Texas 76104, United States
  • Akero Clinical Study Site
    Garland, Texas 75044, United States
  • Akero Clinical Study Site
    Houston, Texas 77058, United States
  • Akero Clinical Study Site
    San Antonio, Texas 78209, United States
  • Akero Clinical Study Site
    San Antonio, Texas 78215, United States
  • Akero Clinical Study Site
    San Antonio, Texas 78229, United States
  • Akero Clinical Study Site
    San Marcos, Texas 78666, United States
  • Akero Clinical Study Site
    Webster, Texas 77598, United States
  • Akero Clinical Study Site
    Charlottesville, Virginia 22908, United States
  • Akero Clinical Study Site
    Richmond, Virginia 23249, United States
  • Akero Clinical Study Site
    Richmond, Virginia 23298, United States
  • Akero Clinical Study Site
    San Juan, 927, Puerto Rico
09

References and documents

Publications

  • Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, Gogia S, Sheikh MY, Behling C, Bedossa P, Shao L, Chan D, Fong E, de Temple B, Shringarpure R, Tillman EJ, Rolph T, Cheng A, Yale K; HARMONY Study Group. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1080-1093. doi: 10.1016/S2468-1253(23)00272-8. Epub 2023 Oct 3. PubMed 37802088 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2024, 38 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 38 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2021
First posted
Feb 23, 2021
StartActual
Feb 16, 2021
Primary completionActual
May 2, 2024
CompletionActual
May 2, 2024
Results first posted
May 8, 2025
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04767529
Responsible party
Sponsor
First posted
Feb 23, 2021
Start date
Feb 16, 2021
Primary completion
May 2, 2024
Completion
May 2, 2024
Results posted
May 8, 2025
Last update
Jun 18, 2025

Study contacts

Akero Study Director
study director · Study Director

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efruxifermin

Start the discussion